2021 Year End Report
2021 Year End Report Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 […]
Market Trends, News, Quarterly Reports
Market Trends, News, Quarterly Reports
Bought Not Sold
Bought Not Sold Why So Many Biopharma M&A Transactions Start Out as Aspirational Licensing Deals Authors: Geoff Meyerson, CEO & Co-Founder
Market Trends, Quarterly Reports
2021 Q3 Report: Global Trends in Biopharma Transactions
2021 Q3 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk deal team members compile key statistics and trends on
Quarterly Reports
iPSC Market Overview
iPSC Market Overview In this report you can find an overview and analysis of the following across the iPSC market: Summary
Quarterly Reports
2021 Q2 Report: Global Trends in Biopharma Transactions
2021 Q2 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk deal team members compile key statistics and trends on
Locust Walk Insights, Market Trends
Crossover Evolution: The Evolving Role of the Crossover Financing Round
Crossover Evolution: The Evolving Role of the Crossover Financing Round Authors: Geoff Meyerson, CEO & Co-Founder Brian Coleman, Global Head of Capital
Locust Walk Insights, Market Trends, Quarterly Reports
2021 Q1 Report: Global Trends in Biopharma Transactions
2021 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk deal team members compile key statistics and trends on
Capital Raising, News
Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC
LOCUST WALK NEWS Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC Geoff Meyerson co-founded Locust
Market Trends, News, Quarterly Reports
Locust Walk 2020 Year End Report
Locust Walk 2020 Year End Report Each quarter our team at Locust Walk compiles key statistics and trends on strategic
Capital Raising, Market Trends, News
Doubling Down: The Power of Asset Diversification in a Time of Robust Access to Capital
Doubling Down Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk